Merck KGaA has narrowed its 2022 sales forecasts for its newly launched pharmaceuticals because of the COVID-19 pandemic, but still expects strong growth from these products and from products and services in its process solutions and electronic businesses.
Merck KGaA has updated sales expectations for its newly launched drugs in 2022, from around €2bn previously to €1.6-1.8bn, including moderating its sales ambitions for the multiple sclerosis drug Mavenclad, because of COVID-19-related effects.
However, peak sales forecasts for Mavenclad (cladribine) remain unchanged, at €1bn to €1.4bn, company CEO Belén Garijo told a briefing...
A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.
The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.
The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.
The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.
Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.
After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.
Swiss major confident that new oncology drugs will fill revenue gap.
